|Bid||0.00 x 1200|
|Ask||0.00 x 800|
|Day's range||49.34 - 51.76|
|52-week range||25.01 - 55.58|
|Beta (5Y monthly)||0.63|
|PE ratio (TTM)||N/A|
|Earnings date||26 Oct 2022 - 31 Oct 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||48.44|
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
Good afternoon, everyone, and thank you to all of the investors and analysts on today's call for being a part of the ClearPoint vision and journey. In the first half of 2022, we continue to make progress across our four-pillar growth strategy, including biologics and drug delivery, functional neurosurgery navigation, therapy and access products, and in achieving global scale.
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -27.54% and 13.54%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?